SCHEMBL5630465

SCHEMBL5630465

CC(C)NC(=O)NCc1nonc1/C(=N\O)Nc1ccc(F)c(Cl)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.47
SMN1; SMN2 Q16637 6/20 0.45
TSHR P16473 2/20 0.43
KDM4E B2RXH2 1/20 0.43
IDO1 P14902 1/20 0.43
MEN1 O00255 5/20 0.43
KMT2A Q03164 5/20 0.43
NPC1 O15118 3/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2D6 P10635 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
RAB9A P51151 2/20 0.40
HTT P42858 1/20 0.40
MAPT P10636 1/20 0.40
CASP3 P42574 1/20 0.40
SENP7 Q9BQF6 1/20 0.40
SLC2A1 P11166 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5630470 1.00 LMNA (0.47) LMNASMN1; SMN2TSHRKDM4EIDO1
SCHEMBL14442493 0.89 SMN1; SMN2 (0.47) LMNASMN1; SMN2TSHRKDM4EMEN1
SCHEMBL5631805 0.89 SMN1; SMN2 (0.47) LMNASMN1; SMN2TSHRKDM4EMEN1
SCHEMBL14462350 0.88 LMNA (0.47) LMNASMN1; SMN2TSHRKDM4EMEN1
SCHEMBL4983160 0.87 SMN1; SMN2 (0.45) LMNASMN1; SMN2TSHRKDM4EMEN1
SCHEMBL4983174 0.87 SMN1; SMN2 (0.45) LMNASMN1; SMN2TSHRKDM4EMEN1
SCHEMBL4971981 0.87 HTT (0.55) LMNASMN1; SMN2TSHRMEN1KMT2A
SCHEMBL5629994 0.86 MEN1 (0.44) LMNASMN1; SMN2TSHRMEN1KMT2A
SCHEMBL5630002 0.86 MEN1 (0.44) LMNASMN1; SMN2TSHRMEN1KMT2A
SCHEMBL5631217 0.86 NPC1 (0.53) LMNASMN1; SMN2IDO1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1971583-B1 N-HYDROXYAMIDINOHETEROCYCLES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE INCYTE CORP (US) 2015-03-25 EP claimed
US-20130177590-A1 N-HYDROXYAMIDINOHETEROCYCLES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE INCYTE CORPORATION (US) 2013-07-11 US claimed
US-8450351-B2 N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase INCYTE CORPORATION (US) 2013-05-28 US claimed
US-20070185165-A1 N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase INCYTE CORPORATION 2007-08-09 US claimed
US-8951536-B2 N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase INCYTE CORPORATION (US) 2015-02-10 US disclosed
US-20130177590-A1 N-HYDROXYAMIDINOHETEROCYCLES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE INCYTE CORPORATION (US) 2013-07-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130177590-A1 N-HYDROXYAMIDINOHETEROCYCLES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE IDO1, IDO2, HNMT LMNA 4520/4885SMN1; SMN2 3175/4885TSHR 2488/4885
US-20070185165-A1 N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase IDO1, IDO2, HNMT LMNA 4520/4885SMN1; SMN2 3175/4885TSHR 2488/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.